Abstract
The success of agents that inhibit tumor necrosis factor (TNF), such as infliximab, adalimumab and etanercept, has led to a desire for orally available small molecules that have a better safety profile and are less costly to produce than current agents. One target for anti-TNF therapy that is currently under investigation is TNF-converting enzyme, which promotes the release of soluble TNF from its membrane-bound precursor. Inhibitors of this enzyme with drug-like properties have been made and tested in the clinic. These inhibitors include TMI-005 and BMS-561392, both of which have entered into phase II clinical trials. This article summarizes preclinical and clinical findings regarding the use of inhibitors of TNF-converting enzyme for the treatment of rheumatoid arthritis.
Key Points
-
Biologic anti-tumor necrosis factor (TNF) agents, including etanercept, infliximab and adalimumab, reduce the severity of symptoms for individuals with rheumatoid arthritis (RA)
-
There is still an unmet medical need for orally available, small-molecule inhibitors of TNF
-
TNF-converting enzyme (TACE) has been validated in preclinical models for the treatment of RA
-
Clinical trials have not determined whether TACE inhibitors have a suitable efficacy or toxicity profile for use in patients with RA
-
TACE-selective inhibitors have been made, and could be used in the future as therapeutics
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Feldmann M et al. (1996) Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 14: 397–440
Papadakis KA and Targan SR (2000) Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 51: 289–298
Hochberg MC et al. (2001) “Stepping-up” from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. Ann Rheum Dis 60 (Suppl 3): iii51–iii54
Voulgari PV and Drosos AA (2006) Adalimumab for rheumatoid arthritis. Expert Opin Biol Ther 6: 1349–1360
Gartlehner G et al. (2006) The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 33: 2398–2408
Jobanputra P et al. (2002) The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 6: 1–110
Blumenauer B et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004525. 10.1002/14651858.CD004525
Navarro-Sarabia F et al. Adalimumab for treating rheumatoid arthritis. Cochrane Database of Systematic Reviews 2005, Issue 3. Art. No.: CD005113. 10.1002/14651858.CD005113.pub2
Quinn MA et al. (2005) Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 52: 27–35
Geletka RC and St Clair EW (2005) Infliximab for the treatment of early rheumatoid arthritis. Expert Opin Biol Ther 5: 405–417
Bongartz T et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275–2285
Keane J et al. (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345: 1098–1104
Askling J et al. (2005) Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64: 1414–1420
Black RA et al. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385: 729–733
Moss ML et al. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385: 733–736
Peschon JJ et al. (1998) An essential role for ectodomain shedding in mammalian development. Science 282: 1281–1284
Conway JG et al. (2001) Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases. J Pharmacol Exp Ther 298: 900–908
Zhang Y et al. (2004) Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S) thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis. J Pharmacol Exp Ther 309: 348–355
Grootveld M and McDermott MF (2003) BMS-561392 (Bristol-Myers Squibb). Curr Opin Investig Drugs 4: 598–602
Zhang Y et al. (2004) Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme. Int Immunopharmacol 4: 1845–1857
Car B (2007) Partnering with pharmacology to probe toxicology. Presented at Society of Toxicology 46th Annual Meeting: 2007 March 25–29, Charlotte, NC
Newton RC et al. (2001) Biology of TACE inhibition. Ann Rheum Dis 60 (Suppl 3): iii25–iii32
Moss ML and Bartsch JW (2004) Therapeutic benefits from targeting of ADAM family members. Biochemistry 43: 7227–7235
Dekkers PE et al. (1999) The effect of a metalloproteinase inhibitor (GI5402) on tumor necrosis factor-alpha (TNF-alpha) and TNF-alpha receptors during human endotoxemia. Blood 94: 2252–2258
Li N et al. (2007) Non-cell autonomous expression of TNF-alpha-converting enzyme ADAM17 is required for normal lymphocyte development. J Immunol 178: 4214–4221
Thabet MM and Huizinga TW (2006) Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis. Curr Opin Investig Drugs 7: 1014–1019
Drummond AH et al. (1999) Preclinical and clinical studies of MMP inhibitors in cancer. Ann NY Acad Sci 878: 228–235
Musso DL et al. (2001) N-hydroxyformamide peptidomimetics as TACE/matrix metalloprotease inhibitors: oral activity via P1' isobutyl substitution. Bioorg Med Chem Lett 11: 2147–2151
Lambert MH et al. (2005) Substrate specificity and novel selective inhibitors of TNF-alpha converting enzyme (TACE) from two-dimensional substrate mapping. Comb Chem High Throughput Screen 8: 327–339
Rabinowitz MH et al. (2001) Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). J Med Chem 44: 4252–4267
Duan JJ et al. (2002) Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships. J Med Chem 45: 4954–4957
Ott GR et al. (2004) Design, synthesis and evaluation of β-benzamido hydroxamic acid inhibitors of TNF-α converting enzyme (TACE) (MEDI 324). Presented at the 228th American Chemical Society National Meeting: 2004 Aug 22–26, Philadelphia, PA
Wang X et al. (2004) Inhibition of tumor necrosis factor-α converting enzyme by a selective antagonist protects brain from focal ischemic injury in rats. Mol Pharmacol 65: 890–896
Duan JJ et al. (2007) Discovery of low nanomolar non-hydroxamate inhibitors of tumor necrosis factor-alpha converting enzyme (TACE). Bioorg Med Chem Lett 17: 266–271
Lombart HG et al. (2007) Design and synthesis of 3,3-piperidine hydroxamate analogs as selective TACE inhibitors. Bioorg Med Chem Lett 17: 4333–4337
Duan JJ et al. (2008) Discovery of β-benzamido hydroxamic acids as potent, selective, and orally bioavailable TACE inhibitors. Bioorg Med Chem Lett 18: 241–246
Hirata T et al. (2001) Discovery of potent, highly selective, and orally active propenohydroxamate TNF-alpha converting enzyme inhibitors (Part 1: MEDI 262 [plus poster]). Presented at the 222nd American Chemical Society National Meeting, 2001 Aug 26–30, Chicago, IL
Bandarage UK et al. (2008) Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones. Bioorg Med Chem Lett 18: 44–48
Sunnarborg SW et al. (2002) Tumor necrosis factor-alpha converting enzyme (TACE) regulates epidermal growth factor receptor ligand availability. J Biol Chem 277: 12838–12845
Sahin U and Blobel CP (2007) Ectodomain shedding of the EGF-receptor ligand epigen is mediated by ADAM17. FEBS Lett 581: 41–44
Sahin U et al. (2004) Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands. J Cell Biol 164: 769–779
Press MF and Lenz HJ (2007) EGFR, HER2 and VEGF pathways: validated targets for cancer treatment. Drugs 67: 2045–2075
Kenny PA and Bissell MJ (2007) Targeting TACE-dependent EGFR ligand shedding in breast cancer. J Clin Invest 117: 337–345
Horiuchi K et al. (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18: 176–188
Zhou BB et al. (2006) Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small-cell lung cancer. Cancer Cell 10: 39–50
Liu PC et al. (2006) Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol Ther 5: 657–664
Schafer B et al. (2004) Distinct ADAM metalloproteinases regulate G protein-coupled receptor-induced cell proliferation and survival. J Biol Chem 279: 47929–47938
Ohtsu H et al. (2006) ADAMs as mediators of EGF receptor transactivation by G protein-coupled receptors. Am J Physiol Cell Physiol 291: C1–C10
Lee DC et al. (2003) TACE/ADAM17 processing of EGFR ligands indicates a role as a physiological convertase. Ann NY Acad Sci 995: 22–38
Black RA et al. (2003) Substrate specificity and inducibility of TACE (tumour necrosis factor alpha-converting enzyme) revisited: the Ala-Val preference, and induced intrinsic activity. Biochem Soc Symp 70: 39–52
Zimina EP et al. (2005) Shedding of collagen XVII ectodomain depends on plasma membrane microenvironment. J Biol Chem 280: 34019–34024
Li N et al. (2007) Metalloproteases regulate T-cell proliferation and effector function via LAG-3. EMBO J 26: 494–504
Horiuchi K et al. (2005) Evaluation of the contributions of ADAMs 9, 12, 15, 17, and 19 to heart development and ectodomain shedding of neuregulins β1 and β2. Dev Biol 283: 459–471
Contin C et al. (2003) Membrane-anchored CD40 is processed by the tumor necrosis factor-alpha-converting enzyme: implications for CD40 signaling. J Biol Chem 278: 32801–32809
Ahmed Z et al. (2006) TACE-induced cleavage of NgR and p75NTR in dorsal root ganglion cultures disinhibits outgrowth and promotes branching of neurites in the presence of inhibitory CNS myelin. FASEB J 20: 1939–1941
Montero JC et al. (2000) Differential shedding of transmembrane neuregulin isoforms by the tumor necrosis factor-alpha-converting enzyme. Mol Cell Neurosci 16: 631–648
Rabie T et al. (2005) Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein V. J Biol Chem 280: 14462–14468
Bergmeier W et al. (2004) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates GPIbα shedding from platelets in vitro and in vivo. Circ Res 95: 677–683
Gardiner EE et al. (2007) Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. J Thromb Haemost 5: 1530–1537
Zhu L et al. (2007) Regulated surface expression and shedding support a dual role for semaphorin 4D in platelet responses to vascular injury. Proc Natl Acad Sci USA 104: 1621–1626
Bohm C et al. (2006) SorLA signaling by regulated intramembrane proteolysis. J Biol Chem 281: 14547–14553
Hermey G et al. (2006) Tumour necrosis factor alpha-converting enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem J 395: 285–293
Shao MX et al. (2003) Tumor necrosis factor alpha-converting enzyme mediates MUC5AC mucin expression in cultured human airway epithelial cells. Proc Natl Acad Sci USA 100: 11618–11623
Thathiah A et al. (2003) Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding. J Biol Chem 278: 3386–3394
Buxbaum JD et al. (1998) Evidence that tumor necrosis factor alpha converting enzyme is involved in regulated alpha-secretase cleavage of the Alzheimer amyloid protein precursor. J Biol Chem 273: 27765–27767
Fabre-Lafay S et al. (2005) Nectin-4, a new serological breast cancer marker, is a substrate for tumor necrosis factor-alpha-converting enzyme (TACE)/ADAM-17. J Biol Chem 280: 19543–19550
Zatovicova M et al. (2005) Ectodomain shedding of the hypoxia-induced carbonic anhydrase IX is a metalloprotease-dependent process regulated by TACE/ADAM17. Br J Cancer 93: 1267–1276
Garton KJ et al. (2001) Tumor necrosis factor-alpha-converting enzyme (ADAM17) mediates the cleavage and shedding of fractalkine (CX3CL1). J Biol Chem 276: 37993–38001
Qu D et al. (2007) Regulated endothelial protein C receptor shedding is mediated by tumor necrosis factor-alpha converting enzyme/ADAM17. J Thromb Haemost 5: 395–402
Garton KJ et al. (2003) Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem 278: 37459–37464
Tsakadze NL et al. (2006) Tumor necrosis factor-alpha-converting enzyme (TACE/ADAM-17) mediates the ectodomain cleavage of intercellular adhesion molecule-1 (ICAM-1). J Biol Chem 281: 3157–3164
Ludeman MJ et al. (2004) Regulated shedding of PAR1 N-terminal exodomain from endothelial cells. J Biol Chem 279: 18592–18599
Wang Y and Sul HS (2006) Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiation. Mol Cell Biol 26: 5421–5435
Heller A (2006) Emerging Company Profile—Amira: Beyond Singulair. BioCentury, the Bernstein Report on BioBusiness, November 13, 2006
Acknowledgements
We thank R Black for comments and suggestions on the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Moss, M., Sklair-Tavron, L. & Nudelman, R. Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. Nat Rev Rheumatol 4, 300–309 (2008). https://doi.org/10.1038/ncprheum0797
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ncprheum0797
This article is cited by
-
The Role of ADAM17 in Inflammation-Related Atherosclerosis
Journal of Cardiovascular Translational Research (2022)
-
Contribution of ADAM17 and related ADAMs in cardiovascular diseases
Cellular and Molecular Life Sciences (2021)
-
Ab locks for improving the selectivity and safety of antibody drugs
Journal of Biomedical Science (2020)
-
TNFα inhibitors as targets for protective therapies in MSA: a viewpoint
Journal of Neuroinflammation (2019)
-
ADAM-17 is expressed in the inflammatory myopathy and is involved with interstitial lung disease
Clinical Rheumatology (2018)